MPL (ASX: MPL) – FY26 Results and Investor Presentation

Medibank Private has reported underlying earnings per share growth of 2.9% to 23.1 cents, maintaining profitability despite an increasingly competitive private health insurance environment. What stands out is the company’s progress in building a diversified earnings base, with the Medibank Health segment contributing approximately 12% of group operating profit and surging 31.3% to $100.7 million for the year.

The health insurance core remains resilient. Resident policyholder numbers grew 1.1%, with net additions of 22.1 thousand despite elevated competition and aggregator marketing pressure. The gross margin held steady at 17.0%, while the operating expense ratio remained at 8.0%, demonstrating that Medibank can absorb competitive pressures without deteriorating profitability. This represents solid operational discipline in a sector where margin compression is a genuine risk.

The company’s capacity to maintain stable margins while growing comes from two sources. First, resident premium revenue expanded 4.5% with disciplined pricing, and second, resident claims growth of 4.4% reflected lower utilisation outside traditional hospital settings combined with improved risk equalisation. The company flagged that a $74.8 million COVID-19 utilisation benefit helped FY26, and this boost will not repeat in FY27, creating a headwind for comparison purposes.

Medibank Health represents the company’s platform play on the broader shift toward community-based and preventative care. The segment achieved revenue growth of 30.8% to $634.8 million, with the acquisition of Better Medical contributing $6.2 million of profit over six months. The primary care arm grew consultations by 26.7%, while acute home health admissions surged 13.7% to support 194,000 hospital bed days saved. These metrics speak to real demand for alternative care settings, though gross margins compressed 180 basis points to 51.5% as the company invested in the Live Better wellbeing program.

Non-resident health insurance proved challenging. Policy units contracted 2.3%, reflecting tighter migration settings and normalisation of large student cohorts acquired after border reopening. Gross profit fell 1.2%, though revenue still grew 5.0%, indicating pricing discipline despite the volume headwind. Management expects stabilisation and solid growth in FY27 as student retention initiatives take effect and worker-visa growth accelerates.

The balance sheet remains strong, with the prescribed capital amount coverage ratio lifting to 1.9x, providing capacity for the company’s M&A ambitions in primary care and wellbeing. The ordinary dividend grew 6.7% to 19.2 cents per share, fully franked, with a payout ratio of 83.0% of underlying earnings, within the stated target range of 75% to 85%.

For investors, the key question is execution on the health transition narrative. Management targets Medibank Health segment profit exceeding $200 million by FY30 and is guiding for growth of approximately 25% in FY27 from a full-year contribution of Better Medical and organic expansion. Resident PHI growth must remain disciplined yet accelerate modestly, while non-resident stabilises. The upcoming FY27 April premium increase and the company’s ability to convert health engagement into retention will be critical data points to monitor.

View the full ASX announcement (PDF)

About MPL (ASX: MPL)

MPL is listed on the Australian Securities Exchange (ASX: MPL).

If you would like to discuss this announcement or how it might affect your portfolio, request a callback or call us on 1300 889 603.